DegronMD

Uniprot ID: P35968

Source protein: Vascular endothelial growth factor receptor 2

Source gene: KDR

Class: DEG_SCF_TRCP1_1

Location: 1346:1352

E3 ligase: BTRC

DEGRON score: 0.7404

ASA_SCORE: 58.7143

COIL: 0.675

CONS_SCORE: 0.4091

DSS_SCORE: 0.701

HELIX: 0.0496

FCONS_SCORE: 1.0038

RIG_SCORE: 0.6473

Degron related mutations and impact score

Mutation	Sample	Cancer	Dataset	Degron	Degron class	Impact score
p.T1339K	TCGA-64-5778	LUAD	TCGA	DSGTTLS	DEG_SCF_TRCP1_1	0.1389
p.T1339K	DO25837	LUAD	ICGC	DSGTTLS	DEG_SCF_TRCP1_1	0.1389
p.S1347L	TCGA-A5-A0G2	UCEC	TCGA	DSGTTLS	DEG_SCF_TRCP1_1	0.7667
p.S1347L	DO41235	UCEC	ICGC	DSGTTLS	DEG_SCF_TRCP1_1	0.7667
p.S1353F	TCGA-D3-A8GI	SKCM	TCGA	DSGTTLS	DEG_SCF_TRCP1_1	0.3056
p.S1353F	DO50284	SKCM	ICGC	DSGTTLS	DEG_SCF_TRCP1_1	0.3056
p.G1337S	TCGA-DF-A2KU	UCEC	TCGA	DSGTTLS	DEG_SCF_TRCP1_1	0.0833
p.G1337S	DO223286	UCEC	ICGC	DSGTTLS	DEG_SCF_TRCP1_1	0.0833
p.P1355A	TCGA-IR-A3LA	CESC	TCGA	DSGTTLS	DEG_SCF_TRCP1_1	0.25
p.P1355A	DO44377	CESC	ICGC	DSGTTLS	DEG_SCF_TRCP1_1	0.25
p.S1338N	DO50970	LICA	ICGC	DSGTTLS	DEG_SCF_TRCP1_1	0.1111
p.T1339I	SIDM01217	Other Blood Cancers	GDSC	DSGTTLS	DEG_SCF_TRCP1_1	0.1389
p.T1339I	SIDM00306	Non-Small Cell Lung Carcinoma	GDSC	DSGTTLS	DEG_SCF_TRCP1_1	0.1389
p.T1339I	ACH-000672	Lung Cancer	CCLE	DSGTTLS	DEG_SCF_TRCP1_1	0.1389
p.T1339I	ACH-002276	Leukemia	CCLE	DSGTTLS	DEG_SCF_TRCP1_1	0.1389
p.T1339I	ACH-002785	Unknown	CCLE	DSGTTLS	DEG_SCF_TRCP1_1	0.1389
p.T1339I	IA-LM	lung	COSMIC	DSGTTLS	DEG_SCF_TRCP1_1	0.1389
p.T1339I	MY-M12	haematopoietic_and_lymphoid_tissue	COSMIC	DSGTTLS	DEG_SCF_TRCP1_1	0.1389

Drug responses associated with KDR mutations

Sample	Cancer	Mutation (In Degron?)	Dataset	Drug	IC50
SIDM00926	UNCLASSIFIED\|lung_NSCLC_not_specified	p.G1145R (No)	GDSC	Ponatinib	16.0729
SIDM00926	UNCLASSIFIED\|lung_NSCLC_not_specified	p.G1145R (No)	GDSC	Cabozantinib	36.0932
SIDM00926	UNCLASSIFIED\|lung_NSCLC_not_specified	p.G1145R (No)	GDSC	Linifanib	22.6549
SIDM00926	UNCLASSIFIED\|lung_NSCLC_not_specified	p.G1145R (No)	GDSC	Foretinib	2.9466
SIDM00926	UNCLASSIFIED\|lung_NSCLC_not_specified	p.G1145R (No)	GDSC	Tivozanib	3.0227
SIDM00926	UNCLASSIFIED\|lung_NSCLC_not_specified	p.G1145R (No)	GDSC	Brivanib, BMS-540215	565.6622
SIDM00926	UNCLASSIFIED\|lung_NSCLC_not_specified	p.G1145R (No)	GDSC	BIBF-1120	417.0341
SIDM00926	UNCLASSIFIED\|lung_NSCLC_not_specified	p.G1145R (No)	GDSC	Axitinib	62.1618
SIDM00926	UNCLASSIFIED\|lung_NSCLC_not_specified	p.G1145R (No)	GDSC	Motesanib	51.6911
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Ponatinib	11.8907
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Cabozantinib	52.3382
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Linifanib	18.2331
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Foretinib	3.3984
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Tivozanib	2.8506
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Brivanib, BMS-540215	89.6645
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	BIBF-1120	10.5909
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Axitinib	37.0818
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Motesanib	38.7849
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Sorafenib	36.405
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Cediranib	171.14
SIDM00747	LUAD\|lung_NSCLC_adenocarcinoma	p.P91fs*3 (No)	GDSC	Foretinib	3.6788
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Sunitinib	201.0901
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Sorafenib	67.5275
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Ponatinib	11.6356
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Cabozantinib	38.6328
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Linifanib	24.438
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Foretinib	24.0044
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Tivozanib	4.1562
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Brivanib, BMS-540215	495.8458
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	BIBF-1120	163.7589
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Axitinib	15.5588
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Motesanib	67.1185
SIDM00719	SCLC\|lung_small_cell_carcinoma	p.E361* (No)	GDSC	Foretinib	7.2808
SIDM00723	UNCLASSIFIED\|lung_NSCLC_not_specified	p.Q738* (No)	GDSC	Ponatinib	4.7347
SIDM00723	UNCLASSIFIED\|lung_NSCLC_not_specified	p.Q738* (No)	GDSC	Cabozantinib	29.857
SIDM00723	UNCLASSIFIED\|lung_NSCLC_not_specified	p.Q738* (No)	GDSC	Linifanib	18.8773
SIDM00723	UNCLASSIFIED\|lung_NSCLC_not_specified	p.Q738* (No)	GDSC	Foretinib	4.1273
SIDM00723	UNCLASSIFIED\|lung_NSCLC_not_specified	p.Q738* (No)	GDSC	Tivozanib	2.6525
SIDM00723	UNCLASSIFIED\|lung_NSCLC_not_specified	p.Q738* (No)	GDSC	Brivanib, BMS-540215	138.0343
SIDM00723	UNCLASSIFIED\|lung_NSCLC_not_specified	p.Q738* (No)	GDSC	BIBF-1120	16.0042
SIDM00723	UNCLASSIFIED\|lung_NSCLC_not_specified	p.Q738* (No)	GDSC	Axitinib	27.466
SIDM00723	UNCLASSIFIED\|lung_NSCLC_not_specified	p.Q738* (No)	GDSC	Motesanib	19.6715
SIDM01150	LUAD\|lung_NSCLC_adenocarcinoma	p.E730* (No)	GDSC	Ponatinib	1.4735
SIDM01150	LUAD\|lung_NSCLC_adenocarcinoma	p.E730* (No)	GDSC	Cabozantinib	18.5354
SIDM01150	LUAD\|lung_NSCLC_adenocarcinoma	p.E730* (No)	GDSC	Linifanib	13.9573
SIDM01150	LUAD\|lung_NSCLC_adenocarcinoma	p.E730* (No)	GDSC	Foretinib	1.1805
SIDM01150	LUAD\|lung_NSCLC_adenocarcinoma	p.E730* (No)	GDSC	Tivozanib	1.8885
SIDM01150	LUAD\|lung_NSCLC_adenocarcinoma	p.E730* (No)	GDSC	Brivanib, BMS-540215	147.5588
SIDM01150	LUAD\|lung_NSCLC_adenocarcinoma	p.E730* (No)	GDSC	BIBF-1120	210.8736
SIDM01150	LUAD\|lung_NSCLC_adenocarcinoma	p.E730* (No)	GDSC	Axitinib	15.336
SIDM01150	LUAD\|lung_NSCLC_adenocarcinoma	p.E730* (No)	GDSC	Motesanib	15.8628
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Ponatinib	0.7662
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Cabozantinib	13.3883
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Linifanib	15.232
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Foretinib	1.169
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Tivozanib	0.7104
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Brivanib, BMS-540215	97.4062
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	BIBF-1120	26.2199
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Axitinib	14.9862
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Motesanib	14.1304
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Sorafenib	19.184
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Cediranib	9.1918
SIDM00345	UNCLASSIFIED\|lung_NSCLC_large_cell	p.H1004N (No)	GDSC	Foretinib	5.187
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Ponatinib	7.5816
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Cabozantinib	75.1586
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Linifanib	14.9552
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Foretinib	51.0935
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Tivozanib	1.572
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Brivanib, BMS-540215	188.827
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	BIBF-1120	296.0943
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Axitinib	19.0517
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Motesanib	8.2212
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Sorafenib	13.542
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Cediranib	9.8013
SIDM00213	THCA\|thyroid	p.P230L (No)	GDSC	Foretinib	4.987
SIDM00189	SKCM\|melanoma	p.E979V (No)	GDSC	Sunitinib	13.01
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Ponatinib	2.9188
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Cabozantinib	38.5657
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Linifanib	24.4282
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Foretinib	7.298
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Tivozanib	3.3041
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Brivanib, BMS-540215	146.1156
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	BIBF-1120	36.3656
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Axitinib	34.4935
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Motesanib	28.4604
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Sorafenib	29.618
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Cediranib	13.981
SIDM00680	COREAD\|large_intestine	p.A10T (No)	GDSC	Foretinib	6.5598
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Ponatinib	8.7734
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Cabozantinib	58.075
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Linifanib	18.1497
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Foretinib	3.4137
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Tivozanib	2.1568
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Brivanib, BMS-540215	182.1331
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	BIBF-1120	29.5172
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Axitinib	5.407
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Motesanib	11.8955
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Sorafenib	5.6511
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Cediranib	188.3
SIDM00749	LUAD\|lung_NSCLC_adenocarcinoma	p.R1126S (No)	GDSC	Foretinib	4.4376
SIDM00151	OV\|ovary	p.A853V (No)	GDSC	Axitinib	24.7641
SIDM00151	OV\|ovary	p.A853V (No)	GDSC	Motesanib	51.1276
SIDM00151	OV\|ovary	p.A853V (No)	GDSC	Sorafenib	14.832
SIDM00151	OV\|ovary	p.A853V (No)	GDSC	Cediranib	0.9851
SIDM00151	OV\|ovary	p.A853V (No)	GDSC	Foretinib	0.5798
SIDM00151	OV\|ovary	p.V171L (No)	GDSC	Axitinib	24.7641
SIDM00151	OV\|ovary	p.V171L (No)	GDSC	Motesanib	51.1276
SIDM00151	OV\|ovary	p.V171L (No)	GDSC	Sorafenib	14.832
SIDM00151	OV\|ovary	p.V171L (No)	GDSC	Cediranib	0.9851
SIDM00151	OV\|ovary	p.V171L (No)	GDSC	Foretinib	0.5798
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Ponatinib	6.7617
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Cabozantinib	3.7394
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Linifanib	11.5115
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Foretinib	0.3556
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Tivozanib	1.2345
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Brivanib, BMS-540215	394.7671
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	BIBF-1120	15.639
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Axitinib	28.5074
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Motesanib	4.9194
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Sorafenib	40.342
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Cediranib	6.2132
SIDM01139	PAAD\|pancreas	p.V567M (No)	GDSC	Foretinib	1.0997
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Sunitinib	69.7013
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Sorafenib	18.9467
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Ponatinib	3.947
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Cabozantinib	9.9083
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Linifanib	5.6349
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Foretinib	5.9943
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Tivozanib	1.1711
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Brivanib, BMS-540215	43.4667
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	BIBF-1120	20.0566
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Axitinib	7.8799
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Motesanib	30.6555
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Sorafenib	4.6434
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Cediranib	8.4465
SIDM00683	PRAD\|prostate	p.A1065T (No)	GDSC	Foretinib	4.473
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Sunitinib	7.6995
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Sorafenib	5.6456
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Ponatinib	6.2969
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Cabozantinib	12.2021
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Linifanib	17.4797
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Foretinib	1.7957
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Tivozanib	1.4097
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Brivanib, BMS-540215	360.8232
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	BIBF-1120	23.6128
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Axitinib	31.6666
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Motesanib	17.3508
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Sorafenib	19.257
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Cediranib	12.764
SIDM00108	SKCM\|melanoma	p.A342V (No)	GDSC	Foretinib	4.0544
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Sunitinib	59.3868
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Sorafenib	31.899
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Ponatinib	6.4962
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Cabozantinib	18.2032
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Linifanib	11.9348
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Foretinib	0.9942
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Tivozanib	1.473
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Brivanib, BMS-540215	156.2331
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	BIBF-1120	178.271
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Axitinib	4.7294
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Motesanib	5.9664
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Sorafenib	8.3177
SIDM00527	COREAD\|large_intestine	p.R1032Q (No)	GDSC	Cediranib	6.1462
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Sunitinib	2.0565
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Sorafenib	4.9994
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Ponatinib	0.2735
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Cabozantinib	1.7755
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Linifanib	4.2428
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Foretinib	0.1908
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Tivozanib	0.7699
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Brivanib, BMS-540215	38.3399
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	BIBF-1120	1.9963
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Axitinib	2.2297
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Motesanib	12.841
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Sorafenib	3.5437
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Cediranib	3.4309
SIDM01007	ALL\|lymphoblastic_leukemia	p.R962H (No)	GDSC	Foretinib	0.4275
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	Ponatinib	10.0266
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	Cabozantinib	78.0231
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	Linifanib	15.9509
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	Foretinib	32.5213
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	Tivozanib	2.4587
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	Brivanib, BMS-540215	413.8767
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	BIBF-1120	220.9022
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	Motesanib	3.1517
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	Sorafenib	28.131
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	Cediranib	42.462
SIDM01174	CESC\|cervix	p.G220V (No)	GDSC	Foretinib	203.12
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Ponatinib	1.3172
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Cabozantinib	28.4658
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Linifanib	18.5661
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Foretinib	1.3236
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Tivozanib	2.1029
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Brivanib, BMS-540215	68.7445
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	BIBF-1120	56.4349
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Axitinib	14.4478
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Motesanib	13.9474
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Sorafenib	47.023
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Cediranib	8.1532
SIDM01190	BLCA\|bladder	p.G1261D (No)	GDSC	Foretinib	3.385
SIDM00052	ESCA\|oesophagus	p.I1330L (No)	GDSC	Sunitinib	4.4854
SIDM00052	ESCA\|oesophagus	p.I1330L (No)	GDSC	Ponatinib	0.8399
SIDM00052	ESCA\|oesophagus	p.I1330L (No)	GDSC	Cabozantinib	50.8389
SIDM00052	ESCA\|oesophagus	p.I1330L (No)	GDSC	Linifanib	9.4311
SIDM00052	ESCA\|oesophagus	p.I1330L (No)	GDSC	Foretinib	18.4258
SIDM00052	ESCA\|oesophagus	p.I1330L (No)	GDSC	Tivozanib	1.6191
SIDM00052	ESCA\|oesophagus	p.I1330L (No)	GDSC	Brivanib, BMS-540215	40.8773
SIDM00052	ESCA\|oesophagus	p.I1330L (No)	GDSC	BIBF-1120	9.6454
SIDM00052	ESCA\|oesophagus	p.I1330L (No)	GDSC	Axitinib	12.7993
SIDM00052	ESCA\|oesophagus	p.I1330L (No)	GDSC	Motesanib	17.5966
SIDM00214	COREAD\|large_intestine	p.R1118Q (No)	GDSC	Cabozantinib	16.8316
SIDM00214	COREAD\|large_intestine	p.R1118Q (No)	GDSC	Linifanib	18.5488
SIDM00214	COREAD\|large_intestine	p.R1118Q (No)	GDSC	Foretinib	0.6811
SIDM00214	COREAD\|large_intestine	p.R1118Q (No)	GDSC	Tivozanib	1.7027
SIDM00214	COREAD\|large_intestine	p.R1118Q (No)	GDSC	Brivanib, BMS-540215	122.9524
SIDM00214	COREAD\|large_intestine	p.R1118Q (No)	GDSC	BIBF-1120	42.7564
SIDM00214	COREAD\|large_intestine	p.R1118Q (No)	GDSC	Axitinib	13.533
SIDM00214	COREAD\|large_intestine	p.R1118Q (No)	GDSC	Motesanib	41.1438
SIDM00214	COREAD\|large_intestine	p.R1118Q (No)	GDSC	Sorafenib	7.7438
SIDM00214	COREAD\|large_intestine	p.R1118Q (No)	GDSC	Cediranib	9.7097
SIDM00214	COREAD\|large_intestine	p.R1066C (No)	GDSC	Cabozantinib	16.8316
SIDM00214	COREAD\|large_intestine	p.R1066C (No)	GDSC	Linifanib	18.5488
SIDM00214	COREAD\|large_intestine	p.R1066C (No)	GDSC	Foretinib	0.6811
SIDM00214	COREAD\|large_intestine	p.R1066C (No)	GDSC	Tivozanib	1.7027
SIDM00214	COREAD\|large_intestine	p.R1066C (No)	GDSC	Brivanib, BMS-540215	122.9524
SIDM00214	COREAD\|large_intestine	p.R1066C (No)	GDSC	BIBF-1120	42.7564
SIDM00214	COREAD\|large_intestine	p.R1066C (No)	GDSC	Axitinib	13.533
SIDM00214	COREAD\|large_intestine	p.R1066C (No)	GDSC	Motesanib	41.1438
SIDM00214	COREAD\|large_intestine	p.R1066C (No)	GDSC	Sorafenib	7.7438
SIDM00214	COREAD\|large_intestine	p.R1066C (No)	GDSC	Cediranib	9.7097
SIDM00214	COREAD\|large_intestine	p.A532V (No)	GDSC	Cabozantinib	16.8316
SIDM00214	COREAD\|large_intestine	p.A532V (No)	GDSC	Linifanib	18.5488
SIDM00214	COREAD\|large_intestine	p.A532V (No)	GDSC	Foretinib	0.6811
SIDM00214	COREAD\|large_intestine	p.A532V (No)	GDSC	Tivozanib	1.7027
SIDM00214	COREAD\|large_intestine	p.A532V (No)	GDSC	Brivanib, BMS-540215	122.9524
SIDM00214	COREAD\|large_intestine	p.A532V (No)	GDSC	BIBF-1120	42.7564
SIDM00214	COREAD\|large_intestine	p.A532V (No)	GDSC	Axitinib	13.533
SIDM00214	COREAD\|large_intestine	p.A532V (No)	GDSC	Motesanib	41.1438
SIDM00214	COREAD\|large_intestine	p.A532V (No)	GDSC	Sorafenib	7.7438
SIDM00214	COREAD\|large_intestine	p.A532V (No)	GDSC	Cediranib	9.7097
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Sunitinib	2.3039
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Sorafenib	7.3363
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Ponatinib	1.0148
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Cabozantinib	5.1141
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Linifanib	11.8922
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Foretinib	0.3304
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Tivozanib	1.6115
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Brivanib, BMS-540215	279.0425
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	BIBF-1120	2.6344
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Axitinib	4.2957
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Motesanib	25.2017
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Sorafenib	7.5102
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Cediranib	8.3902
SIDM01088	UNCLASSIFIED\|endometrium	p.D710A (No)	GDSC	Foretinib	1.992
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	Sunitinib	5.2071
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	Sorafenib	57.2003
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	Ponatinib	8.8614
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	Cabozantinib	8.4821
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	Linifanib	12.7898
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	Foretinib	0.5757
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	Tivozanib	2.2082
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	Brivanib, BMS-540215	22.2403
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	BIBF-1120	3.8194
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	Axitinib	9.4445
SIDM00188	KIRC\|kidney	p.A248G (No)	GDSC	Motesanib	10.4975
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Sunitinib	159.8703
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Sorafenib	19.7335
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Ponatinib	6.0105
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Cabozantinib	46.6586
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Linifanib	28.1567
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Foretinib	1.9059
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Tivozanib	0.8688
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Brivanib, BMS-540215	221.9895
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	BIBF-1120	22.4691
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Axitinib	43.702
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Motesanib	39.1268
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Sorafenib	22.728
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Cediranib	12.633
SIDM00292	SCLC\|lung_small_cell_carcinoma	p.L1156F (No)	GDSC	Foretinib	12.426
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Sunitinib	15.1007
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Sorafenib	7.8445
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Ponatinib	4.7966
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Cabozantinib	8.4184
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Linifanib	9.7802
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Foretinib	1.1718
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Tivozanib	1.0895
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Brivanib, BMS-540215	8.019
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	BIBF-1120	6.7195
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Axitinib	2.999
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Motesanib	24.3704
SIDM00482	LCML\|chronic_myeloid_leukaemia	p.K1270Q (No)	GDSC	Foretinib	1.7865
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	Sunitinib	2.8272
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	Sorafenib	6.9852
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	Ponatinib	5.7115
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	Cabozantinib	42.8823
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	Linifanib	11.4189
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	Foretinib	3.0561
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	Tivozanib	1.3034
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	Brivanib, BMS-540215	52.7285
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	BIBF-1120	38.929
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	Axitinib	9.7418
SIDM01039	UNCLASSIFIED\|urogenital_system_other	p.G424A (No)	GDSC	Motesanib	18.8844
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Sunitinib	5.8574
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Sorafenib	3.2571
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Ponatinib	0.6349
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Cabozantinib	4.4868
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Linifanib	8.7913
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Foretinib	0.3712
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Tivozanib	1.0062
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Brivanib, BMS-540215	63.0613
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	BIBF-1120	22.0568
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Axitinib	5.4185
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Motesanib	21.9259
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Sorafenib	5.6057
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Cediranib	6.792
SIDM00388	UNCLASSIFIED\|B_cell_leukemia	p.G99E (No)	GDSC	Foretinib	4.5486
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Ponatinib	1.7228
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Cabozantinib	7.7925
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Linifanib	7.4125
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Foretinib	0.6555
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Tivozanib	1.2145
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Brivanib, BMS-540215	39.1671
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	BIBF-1120	1.9696
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Axitinib	11.1658
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Motesanib	3.2422
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Sorafenib	8.8626
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Cediranib	10.243
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.G539R (No)	GDSC	Foretinib	3.7573
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Ponatinib	1.7228
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Cabozantinib	7.7925
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Linifanib	7.4125
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Foretinib	0.6555
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Tivozanib	1.2145
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Brivanib, BMS-540215	39.1671
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	BIBF-1120	1.9696
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Axitinib	11.1658
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Motesanib	3.2422
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Sorafenib	8.8626
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Cediranib	10.243
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58G (No)	GDSC	Foretinib	3.7573
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Ponatinib	1.7228
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Cabozantinib	7.7925
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Linifanib	7.4125
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Foretinib	0.6555
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Tivozanib	1.2145
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Brivanib, BMS-540215	39.1671
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	BIBF-1120	1.9696
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Axitinib	11.1658
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Motesanib	3.2422
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Sorafenib	8.8626
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Cediranib	10.243
SIDM00792	SCLC\|lung_small_cell_carcinoma	p.D58Y (No)	GDSC	Foretinib	3.7573
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	Ponatinib	0.8922
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	Cabozantinib	52.6341
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	Linifanib	12.797
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	Foretinib	7.9117
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	Tivozanib	1.735
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	Brivanib, BMS-540215	49.6068
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	BIBF-1120	9.7502
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	Axitinib	16.5624
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	Sorafenib	10.585
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	Cediranib	8.9193
SIDM00853	UNCLASSIFIED\|soft_tissue_other	p.P230S (No)	GDSC	Foretinib	2.6561
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Ponatinib	1.1816
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Cabozantinib	42.0625
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Linifanib	10.7273
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Foretinib	2.8306
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Tivozanib	1.4343
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Brivanib, BMS-540215	68.9695
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	BIBF-1120	15.4151
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Axitinib	17.1661
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Motesanib	2.8772
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Sorafenib	8.8517
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Cediranib	5.4692
SIDM00333	UCEC\|endometrium	p.A750T (No)	GDSC	Foretinib	7.9407
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Ponatinib	3.9322
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Cabozantinib	100.7682
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Linifanib	12.8922
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Foretinib	23.5981
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Tivozanib	2.5251
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Brivanib, BMS-540215	58.8655
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	BIBF-1120	21.643
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Axitinib	33.6251
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Motesanib	15.0905
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Sorafenib	4.9166
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Cediranib	14.216
SIDM00523	SCLC\|lung_small_cell_carcinoma	p.D558A (No)	GDSC	Foretinib	2.6383
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Ponatinib	1.1381
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Cabozantinib	36.0491
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Linifanib	5.7148
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Foretinib	1.187
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Tivozanib	0.9461
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Brivanib, BMS-540215	17.4625
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	BIBF-1120	10.8939
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Axitinib	2.4148
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Motesanib	4.9658
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Sorafenib	8.0689
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Cediranib	5.4135
SIDM00999	BLCA\|bladder	p.D958Y (No)	GDSC	Foretinib	1.4814
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Ponatinib	9.6931
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Cabozantinib	75.7912
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Linifanib	16.2906
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Foretinib	1.0591
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Tivozanib	2.2676
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Brivanib, BMS-540215	336.4549
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	BIBF-1120	408.6594
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Axitinib	14.8997
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Motesanib	17.507
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Sorafenib	23.461
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Cediranib	19.488
SIDM01101	NB\|neuroblastoma	p.L31P (No)	GDSC	Foretinib	3.9339
SIDM00217	COREAD\|large_intestine	p.A1030V (No)	GDSC	Cabozantinib	12.0756
SIDM00217	COREAD\|large_intestine	p.A1030V (No)	GDSC	Linifanib	18.1376
SIDM00217	COREAD\|large_intestine	p.A1030V (No)	GDSC	Foretinib	1.6723
SIDM00217	COREAD\|large_intestine	p.A1030V (No)	GDSC	Tivozanib	2.681
SIDM00217	COREAD\|large_intestine	p.A1030V (No)	GDSC	Brivanib, BMS-540215	386.8326
SIDM00217	COREAD\|large_intestine	p.A1030V (No)	GDSC	BIBF-1120	16.5032
SIDM00217	COREAD\|large_intestine	p.A772V (No)	GDSC	Cabozantinib	12.0756
SIDM00217	COREAD\|large_intestine	p.A772V (No)	GDSC	Linifanib	18.1376
SIDM00217	COREAD\|large_intestine	p.A772V (No)	GDSC	Foretinib	1.6723
SIDM00217	COREAD\|large_intestine	p.A772V (No)	GDSC	Tivozanib	2.681
SIDM00217	COREAD\|large_intestine	p.A772V (No)	GDSC	Brivanib, BMS-540215	386.8326
SIDM00217	COREAD\|large_intestine	p.A772V (No)	GDSC	BIBF-1120	16.5032
SIDM00217	COREAD\|large_intestine	p.R725H (No)	GDSC	Cabozantinib	12.0756
SIDM00217	COREAD\|large_intestine	p.R725H (No)	GDSC	Linifanib	18.1376
SIDM00217	COREAD\|large_intestine	p.R725H (No)	GDSC	Foretinib	1.6723
SIDM00217	COREAD\|large_intestine	p.R725H (No)	GDSC	Tivozanib	2.681
SIDM00217	COREAD\|large_intestine	p.R725H (No)	GDSC	Brivanib, BMS-540215	386.8326
SIDM00217	COREAD\|large_intestine	p.R725H (No)	GDSC	BIBF-1120	16.5032
SIDM00217	COREAD\|large_intestine	p.A45D (No)	GDSC	Cabozantinib	12.0756
SIDM00217	COREAD\|large_intestine	p.A45D (No)	GDSC	Linifanib	18.1376
SIDM00217	COREAD\|large_intestine	p.A45D (No)	GDSC	Foretinib	1.6723
SIDM00217	COREAD\|large_intestine	p.A45D (No)	GDSC	Tivozanib	2.681
SIDM00217	COREAD\|large_intestine	p.A45D (No)	GDSC	Brivanib, BMS-540215	386.8326
SIDM00217	COREAD\|large_intestine	p.A45D (No)	GDSC	BIBF-1120	16.5032
SIDM00140	SKCM\|melanoma	p.S1037L (No)	GDSC	Ponatinib	5.6195
SIDM00140	SKCM\|melanoma	p.S1037L (No)	GDSC	Linifanib	13.1936
SIDM00140	SKCM\|melanoma	p.S1037L (No)	GDSC	Tivozanib	1.2935
SIDM00140	SKCM\|melanoma	p.S1037L (No)	GDSC	Brivanib, BMS-540215	121.0887
SIDM00140	SKCM\|melanoma	p.S1037L (No)	GDSC	BIBF-1120	5.8392
SIDM00140	SKCM\|melanoma	p.S1037L (No)	GDSC	Axitinib	22.5146
SIDM00140	SKCM\|melanoma	p.S1037L (No)	GDSC	Motesanib	4.4263
SIDM00140	SKCM\|melanoma	p.S1037L (No)	GDSC	Sorafenib	6.2025
SIDM00140	SKCM\|melanoma	p.S1037L (No)	GDSC	Cediranib	5.3822
SIDM00140	SKCM\|melanoma	p.S1037L (No)	GDSC	Foretinib	0.5815
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Sunitinib	7.4015
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Sorafenib	34.6648
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Ponatinib	7.2309
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Cabozantinib	72.271
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Linifanib	14.4617
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Foretinib	1.9945
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Tivozanib	1.7457
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Brivanib, BMS-540215	81.8243
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	BIBF-1120	149.2041
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Axitinib	10.3096
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Motesanib	15.9469
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Sorafenib	6.0739
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Cediranib	8.2906
SIDM00948	UNCLASSIFIED\|Burkitt_lymphoma	p.E979G (No)	GDSC	Foretinib	1.8461
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Sunitinib	96.5078
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Sorafenib	10.2261
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Ponatinib	10.2267
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Cabozantinib	102.8585
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Linifanib	20.6363
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Foretinib	2.4959
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Tivozanib	2.1854
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Brivanib, BMS-540215	55.9392
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	BIBF-1120	8.7862
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Axitinib	3.8457
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Motesanib	6.7148
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Sorafenib	8.8176
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Cediranib	13.265
SIDM01120	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.S310A (No)	GDSC	Foretinib	1.636
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	Ponatinib	8.745
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	Cabozantinib	12.6272
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	Linifanib	20.7968
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	Foretinib	1.1638
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	Tivozanib	2.0955
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	Brivanib, BMS-540215	133.1914
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	BIBF-1120	15.9989
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	Axitinib	19.6861
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	Sorafenib	67.14
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	Cediranib	5.1561
SIDM00352	UNCLASSIFIED\|ovary	p.G99A (No)	GDSC	Foretinib	7.6524
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	Sunitinib	4.5223
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	Sorafenib	2.2196
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	Ponatinib	0.0022
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	Cabozantinib	0.3281
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	Linifanib	11.3611
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	Foretinib	0.1495
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	Tivozanib	0.0187
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	Brivanib, BMS-540215	12.6222
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	BIBF-1120	0.611
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	Axitinib	0.5387
SIDM01217	ALL\|leukemia	p.T1339I (Yes)	GDSC	Motesanib	21.6035
SIDM00216	COREAD\|large_intestine	p.S153T (No)	GDSC	Cabozantinib	6.0987
SIDM00216	COREAD\|large_intestine	p.S153T (No)	GDSC	Linifanib	6.5206
SIDM00216	COREAD\|large_intestine	p.S153T (No)	GDSC	Foretinib	0.3489
SIDM00216	COREAD\|large_intestine	p.S153T (No)	GDSC	Tivozanib	0.889
SIDM00216	COREAD\|large_intestine	p.S153T (No)	GDSC	Brivanib, BMS-540215	44.5765
SIDM00216	COREAD\|large_intestine	p.S153T (No)	GDSC	BIBF-1120	5.408
SIDM00216	COREAD\|large_intestine	p.S153T (No)	GDSC	Sorafenib	7.7286
SIDM00216	COREAD\|large_intestine	p.S153T (No)	GDSC	Cediranib	4.8238
SIDM00216	COREAD\|large_intestine	p.S153T (No)	GDSC	Foretinib	0.4705
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Sunitinib	189.499
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Sorafenib	61.3342
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Ponatinib	13.9216
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Cabozantinib	55.7164
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Linifanib	26.1518
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Foretinib	7.5179
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Tivozanib	2.4116
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Brivanib, BMS-540215	66.1763
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	BIBF-1120	39.5796
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Axitinib	50.4847
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Motesanib	57.5889
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Sorafenib	7.9982
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Cediranib	11.404
SIDM00282	COREAD\|large_intestine	p.H1213Q (No)	GDSC	Foretinib	8.0375
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Sunitinib	189.499
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Sorafenib	61.3342
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Ponatinib	13.9216
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Cabozantinib	55.7164
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Linifanib	26.1518
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Foretinib	7.5179
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Tivozanib	2.4116
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Brivanib, BMS-540215	66.1763
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	BIBF-1120	39.5796
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Axitinib	50.4847
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Motesanib	57.5889
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Sorafenib	7.9982
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Cediranib	11.404
SIDM00282	COREAD\|large_intestine	p.I915T (No)	GDSC	Foretinib	8.0375
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Sunitinib	189.499
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Sorafenib	61.3342
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Ponatinib	13.9216
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Cabozantinib	55.7164
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Linifanib	26.1518
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Foretinib	7.5179
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Tivozanib	2.4116
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Brivanib, BMS-540215	66.1763
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	BIBF-1120	39.5796
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Axitinib	50.4847
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Motesanib	57.5889
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Sorafenib	7.9982
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Cediranib	11.404
SIDM00282	COREAD\|large_intestine	p.G424D (No)	GDSC	Foretinib	8.0375
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Ponatinib	10.0449
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Cabozantinib	100.1288
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Linifanib	17.5004
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Foretinib	6.6399
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Tivozanib	2.5112
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Brivanib, BMS-540215	327.6841
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	BIBF-1120	3.4766
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Axitinib	6.6269
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Motesanib	11.2899
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Sorafenib	10.44
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Cediranib	5.5196
SIDM00479	ESCA\|oesophagus	p.G539R (No)	GDSC	Foretinib	1.9328
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Sunitinib	0.4368
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Sorafenib	0.9119
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Ponatinib	0.1197
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Cabozantinib	2.0837
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Linifanib	8.0753
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Foretinib	0.4609
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Tivozanib	0.604
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Brivanib, BMS-540215	73.4735
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	BIBF-1120	2.5739
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Axitinib	7.6527
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Motesanib	31.6936
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Sorafenib	6.2706
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Cediranib	9.8117
SIDM00150	COREAD\|large_intestine	p.S26G (No)	GDSC	Foretinib	0.0941
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Ponatinib	5.8749
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Cabozantinib	153.8741
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Linifanib	30.0118
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Foretinib	153.8741
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Tivozanib	3.8117
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Brivanib, BMS-540215	106.3503
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	BIBF-1120	2.6491
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Axitinib	23.5688
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Motesanib	49.9606
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Sorafenib	30.643
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Cediranib	96.887
SIDM01084	UNCLASSIFIED\|osteosarcoma	p.G671E (No)	GDSC	Foretinib	3.666
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Sunitinib	13.3382
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Sorafenib	19.1682
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Ponatinib	5.1901
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Cabozantinib	43.5058
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Linifanib	5.9476
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Foretinib	4.6612
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Tivozanib	1.2658
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Brivanib, BMS-540215	19.0818
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	BIBF-1120	2.603
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Axitinib	7.0831
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Motesanib	20.8095
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Sorafenib	5.569
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Cediranib	11.504
SIDM00640	MESO\|mesothelioma	p.S1303N (No)	GDSC	Foretinib	4.8957
SIDM00715	LUAD\|lung_NSCLC_adenocarcinoma	p.G152V (No)	GDSC	Ponatinib	0.2621
SIDM00715	LUAD\|lung_NSCLC_adenocarcinoma	p.G152V (No)	GDSC	Cabozantinib	14.9572
SIDM00715	LUAD\|lung_NSCLC_adenocarcinoma	p.G152V (No)	GDSC	Linifanib	10.2624
SIDM00715	LUAD\|lung_NSCLC_adenocarcinoma	p.G152V (No)	GDSC	Foretinib	0.7612
SIDM00715	LUAD\|lung_NSCLC_adenocarcinoma	p.G152V (No)	GDSC	Tivozanib	1.3803
SIDM00715	LUAD\|lung_NSCLC_adenocarcinoma	p.G152V (No)	GDSC	Brivanib, BMS-540215	121.4884
SIDM00715	LUAD\|lung_NSCLC_adenocarcinoma	p.G152V (No)	GDSC	BIBF-1120	14.4091
SIDM00715	LUAD\|lung_NSCLC_adenocarcinoma	p.G152V (No)	GDSC	Axitinib	26.8735
SIDM00715	LUAD\|lung_NSCLC_adenocarcinoma	p.G152V (No)	GDSC	Motesanib	7.629
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Ponatinib	6.5232
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Cabozantinib	6.5099
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Linifanib	9.2766
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Foretinib	0.706
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Tivozanib	1.133
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Brivanib, BMS-540215	20.668
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	BIBF-1120	6.0099
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Axitinib	3.5098
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Motesanib	3.3372
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Sorafenib	6.9458
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Cediranib	6.8927
SIDM01183	UNCLASSIFIED\|lung_NSCLC_carcinoid	p.D1064Y (No)	GDSC	Foretinib	2.3879
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Sunitinib	39.9798
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Sorafenib	14.6424
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Ponatinib	5.6122
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Cabozantinib	9.7866
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Linifanib	9.8819
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Foretinib	1.3792
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Tivozanib	1.6792
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Brivanib, BMS-540215	108.4196
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	BIBF-1120	5.8337
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Axitinib	28.417
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Motesanib	31.2238
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Axitinib	8.7656
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Sorafenib	16.898
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Cediranib	8.2377
SIDM00954	BRCA\|breast	p.R106W (No)	GDSC	Foretinib	0.8825
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Sunitinib	4.3538
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Sorafenib	4.3968
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Ponatinib	2.0749
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Cabozantinib	11.4291
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Linifanib	9.6852
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Foretinib	0.8607
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Tivozanib	1.2222
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Brivanib, BMS-540215	25.7971
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	BIBF-1120	21.4575
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Axitinib	4.3721
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Motesanib	16.2033
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Sorafenib	13.447
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Cediranib	31.636
SIDM00422	UNCLASSIFIED\|Hodgkin_lymphoma	p.V1207E (No)	GDSC	Foretinib	2.3568
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Ponatinib	1.6564
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Cabozantinib	14.2209
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Linifanib	9.391
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Foretinib	0.9916
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Tivozanib	1.3233
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Brivanib, BMS-540215	54.9229
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	BIBF-1120	90.8873
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Axitinib	7.279
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Motesanib	12.7822
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Sorafenib	10.469
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Cediranib	6.0229
SIDM00789	COREAD\|large_intestine	p.S925F (No)	GDSC	Foretinib	2.3277
SIDM00534	COREAD\|large_intestine	p.D1312N (No)	GDSC	Ponatinib	6.8973
SIDM00534	COREAD\|large_intestine	p.D1312N (No)	GDSC	Cabozantinib	34.719
SIDM00534	COREAD\|large_intestine	p.D1312N (No)	GDSC	Linifanib	13.547
SIDM00534	COREAD\|large_intestine	p.D1312N (No)	GDSC	Foretinib	4.5289
SIDM00534	COREAD\|large_intestine	p.D1312N (No)	GDSC	Tivozanib	1.7085
SIDM00534	COREAD\|large_intestine	p.D1312N (No)	GDSC	Brivanib, BMS-540215	95.0311
SIDM00534	COREAD\|large_intestine	p.D1312N (No)	GDSC	BIBF-1120	20.297
SIDM00534	COREAD\|large_intestine	p.D1312N (No)	GDSC	Axitinib	7.3465
SIDM00534	COREAD\|large_intestine	p.D1312N (No)	GDSC	Motesanib	18.0454
SIDM00534	COREAD\|large_intestine	p.S1290N (No)	GDSC	Ponatinib	6.8973
SIDM00534	COREAD\|large_intestine	p.S1290N (No)	GDSC	Cabozantinib	34.719
SIDM00534	COREAD\|large_intestine	p.S1290N (No)	GDSC	Linifanib	13.547
SIDM00534	COREAD\|large_intestine	p.S1290N (No)	GDSC	Foretinib	4.5289
SIDM00534	COREAD\|large_intestine	p.S1290N (No)	GDSC	Tivozanib	1.7085
SIDM00534	COREAD\|large_intestine	p.S1290N (No)	GDSC	Brivanib, BMS-540215	95.0311
SIDM00534	COREAD\|large_intestine	p.S1290N (No)	GDSC	BIBF-1120	20.297
SIDM00534	COREAD\|large_intestine	p.S1290N (No)	GDSC	Axitinib	7.3465
SIDM00534	COREAD\|large_intestine	p.S1290N (No)	GDSC	Motesanib	18.0454
SIDM00534	COREAD\|large_intestine	p.R944Q (No)	GDSC	Ponatinib	6.8973
SIDM00534	COREAD\|large_intestine	p.R944Q (No)	GDSC	Cabozantinib	34.719
SIDM00534	COREAD\|large_intestine	p.R944Q (No)	GDSC	Linifanib	13.547
SIDM00534	COREAD\|large_intestine	p.R944Q (No)	GDSC	Foretinib	4.5289
SIDM00534	COREAD\|large_intestine	p.R944Q (No)	GDSC	Tivozanib	1.7085
SIDM00534	COREAD\|large_intestine	p.R944Q (No)	GDSC	Brivanib, BMS-540215	95.0311
SIDM00534	COREAD\|large_intestine	p.R944Q (No)	GDSC	BIBF-1120	20.297
SIDM00534	COREAD\|large_intestine	p.R944Q (No)	GDSC	Axitinib	7.3465
SIDM00534	COREAD\|large_intestine	p.R944Q (No)	GDSC	Motesanib	18.0454
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Sunitinib	336.6649
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Sorafenib	168.3325
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Ponatinib	17.9617
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Cabozantinib	215.4655
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Linifanib	41.3801
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Foretinib	215.4655
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Tivozanib	4.3501
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Brivanib, BMS-540215	344.8377
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	BIBF-1120	35.6694
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Axitinib	84.1662
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Motesanib	84.1662
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Sorafenib	120.66
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Cediranib	138.91
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.G942E (No)	GDSC	Foretinib	6.4082
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Sunitinib	336.6649
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Sorafenib	168.3325
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Ponatinib	17.9617
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Cabozantinib	215.4655
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Linifanib	41.3801
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Foretinib	215.4655
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Tivozanib	4.3501
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Brivanib, BMS-540215	344.8377
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	BIBF-1120	35.6694
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Axitinib	84.1662
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Motesanib	84.1662
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Sorafenib	120.66
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Cediranib	138.91
SIDM01175	UNCLASSIFIED\|fibrosarcoma	p.P839S (No)	GDSC	Foretinib	6.4082
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Sunitinib	3.5046
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Sorafenib	17.0004
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Ponatinib	1.5918
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Cabozantinib	16.1575
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Linifanib	8.498
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Foretinib	0.5605
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Tivozanib	1.2581
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Brivanib, BMS-540215	26.0028
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	BIBF-1120	3.0891
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Axitinib	7.9138
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Motesanib	12.8484
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Sorafenib	5.503
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Cediranib	5.8685
SIDM00245	SCLC\|lung_small_cell_carcinoma	p.T660P (No)	GDSC	Foretinib	3.1113
SIDM01220	GBM\|glioma	p.L707I (No)	GDSC	Ponatinib	0.5541
SIDM01220	GBM\|glioma	p.L707I (No)	GDSC	Cabozantinib	14.0564
SIDM01220	GBM\|glioma	p.L707I (No)	GDSC	Linifanib	11.3852
SIDM01220	GBM\|glioma	p.L707I (No)	GDSC	Foretinib	1.7942
SIDM01220	GBM\|glioma	p.L707I (No)	GDSC	Tivozanib	1.4303
SIDM01220	GBM\|glioma	p.L707I (No)	GDSC	Brivanib, BMS-540215	72.3833
SIDM01220	GBM\|glioma	p.L707I (No)	GDSC	BIBF-1120	72.1527
SIDM01220	GBM\|glioma	p.L707I (No)	GDSC	Axitinib	3.8696
SIDM01220	GBM\|glioma	p.L707I (No)	GDSC	Motesanib	14.2845
SIDM00735	SCLC\|lung_small_cell_carcinoma	p.K939R (No)	GDSC	Ponatinib	5.945
SIDM00735	SCLC\|lung_small_cell_carcinoma	p.K939R (No)	GDSC	Cabozantinib	55.1183
SIDM00735	SCLC\|lung_small_cell_carcinoma	p.K939R (No)	GDSC	Linifanib	11.8852
SIDM00735	SCLC\|lung_small_cell_carcinoma	p.K939R (No)	GDSC	Foretinib	2.3243
SIDM00735	SCLC\|lung_small_cell_carcinoma	p.K939R (No)	GDSC	Tivozanib	1.487
SIDM00735	SCLC\|lung_small_cell_carcinoma	p.K939R (No)	GDSC	Brivanib, BMS-540215	72.109
SIDM00735	SCLC\|lung_small_cell_carcinoma	p.K939R (No)	GDSC	BIBF-1120	18.5397
SIDM00735	SCLC\|lung_small_cell_carcinoma	p.K939R (No)	GDSC	Axitinib	5.4859
SIDM00735	SCLC\|lung_small_cell_carcinoma	p.K939R (No)	GDSC	Motesanib	15.2917
SIDM00735	SCLC\|lung_small_cell_carcinoma	p.K939R (No)	GDSC	Foretinib	4.8586
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Ponatinib	12.0185
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Cabozantinib	107.4008
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Linifanib	18.6537
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Foretinib	5.4278
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Tivozanib	2.2473
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Brivanib, BMS-540215	290.7788
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	BIBF-1120	25.7926
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Axitinib	39.1958
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Motesanib	13.0462
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Sorafenib	22.398
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Cediranib	9.5587
SIDM00545	SKCM\|melanoma	p.S1281F (No)	GDSC	Foretinib	4.0516
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Ponatinib	0.6979
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Cabozantinib	63.4851
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Linifanib	15.3008
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Foretinib	1.5628
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Tivozanib	2.0611
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Brivanib, BMS-540215	61.713
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	BIBF-1120	38.9053
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Axitinib	2.2993
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Motesanib	0.5405
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Sorafenib	65.631
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Cediranib	86.136
SIDM00120	PRAD\|prostate	p.C466F (No)	GDSC	Foretinib	14.952
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Ponatinib	15.1296
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Cabozantinib	144.2481
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Linifanib	14.9174
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Foretinib	121.8592
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Tivozanib	2.653
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Brivanib, BMS-540215	391.7555
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	BIBF-1120	110.2938
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Axitinib	58.0569
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Motesanib	58.0907
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Sorafenib	68.959
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Cediranib	28.532
SIDM00114	MESO\|mesothelioma	p.P992S (No)	GDSC	Foretinib	29.013
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Ponatinib	15.1296
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Cabozantinib	144.2481
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Linifanib	14.9174
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Foretinib	121.8592
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Tivozanib	2.653
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Brivanib, BMS-540215	391.7555
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	BIBF-1120	110.2938
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Axitinib	58.0569
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Motesanib	58.0907
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Sorafenib	68.959
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Cediranib	28.532
SIDM00114	MESO\|mesothelioma	p.N721K (No)	GDSC	Foretinib	29.013
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Sunitinib	1.9017
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Sorafenib	2.3762
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Ponatinib	1.4001
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Cabozantinib	21.9398
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Linifanib	6.6504
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Foretinib	1.2469
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Tivozanib	0.5962
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Brivanib, BMS-540215	47.8914
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	BIBF-1120	23.6798
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Axitinib	2.5424
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Motesanib	3.4761
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Sorafenib	4.0768
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Cediranib	2.119
SIDM00949	UNCLASSIFIED\|lymphoid_neoplasm_other	p.G255R (No)	GDSC	Foretinib	0.2497
SIDM00144	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G1304C (No)	GDSC	Ponatinib	0.8208
SIDM00144	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G1304C (No)	GDSC	Cabozantinib	44.1996
SIDM00144	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G1304C (No)	GDSC	Linifanib	10.1372
SIDM00144	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G1304C (No)	GDSC	Foretinib	2.7056
SIDM00144	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G1304C (No)	GDSC	Tivozanib	1.3669
SIDM00144	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G1304C (No)	GDSC	Brivanib, BMS-540215	84.5607
SIDM00144	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G1304C (No)	GDSC	BIBF-1120	17.5181
SIDM00144	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G1304C (No)	GDSC	Axitinib	3.3474
SIDM00144	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G1304C (No)	GDSC	Motesanib	21.1764
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Sunitinib	4.5073
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Sorafenib	6.5871
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Ponatinib	0.7424
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Cabozantinib	23.0587
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Linifanib	6.1171
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Foretinib	0.4757
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Tivozanib	2.2074
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Brivanib, BMS-540215	114.9605
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	BIBF-1120	12.7982
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Axitinib	15.7432
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Motesanib	27.8266
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Sorafenib	43.153
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Cediranib	5.1844
SIDM00225	SKCM\|melanoma	p.M191I (No)	GDSC	Foretinib	3.7209
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Sunitinib	2.8236
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Sorafenib	5.9691
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Ponatinib	0.1731
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Cabozantinib	4.5922
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Linifanib	9.659
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Foretinib	0.3978
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Tivozanib	0.679
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Brivanib, BMS-540215	36.5429
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	BIBF-1120	1.6019
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Axitinib	5.7949
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Motesanib	10.1078
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Sorafenib	2.3029
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Cediranib	6.4664
SIDM00451	ALL\|lymphoblastic_T_cell_leukaemia	p.R791Q (No)	GDSC	Foretinib	0.6028
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Ponatinib	0.9495
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Cabozantinib	4.5532
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Linifanib	10.0417
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Foretinib	1.2213
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Tivozanib	2.2374
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Brivanib, BMS-540215	172.8152
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	BIBF-1120	12.2604
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Axitinib	38.0394
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Motesanib	34.3232
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Sorafenib	176.57
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Cediranib	93.26
SIDM00726	LUAD\|lung_NSCLC_adenocarcinoma	p.S1266L (No)	GDSC	Foretinib	95.098
SIDM00080	SKCM\|melanoma	p.S633F (No)	GDSC	Ponatinib	7.2627
SIDM00080	SKCM\|melanoma	p.S633F (No)	GDSC	Cabozantinib	17.7799
SIDM00080	SKCM\|melanoma	p.S633F (No)	GDSC	Linifanib	26.4944
SIDM00080	SKCM\|melanoma	p.S633F (No)	GDSC	Foretinib	1.7688
SIDM00080	SKCM\|melanoma	p.S633F (No)	GDSC	Tivozanib	4.029
SIDM00080	SKCM\|melanoma	p.S633F (No)	GDSC	Brivanib, BMS-540215	190.4419
SIDM00080	SKCM\|melanoma	p.S633F (No)	GDSC	BIBF-1120	17.7702
SIDM00080	SKCM\|melanoma	p.S633F (No)	GDSC	Axitinib	5.259
SIDM00080	SKCM\|melanoma	p.S633F (No)	GDSC	Motesanib	14.2751
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Ponatinib	0.7801
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Cabozantinib	42.429
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Linifanib	22.5105
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Foretinib	2.0655
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Tivozanib	1.9378
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Brivanib, BMS-540215	415.2646
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	BIBF-1120	62.4198
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Axitinib	6.1561
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Motesanib	6.275
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Sorafenib	1743.4
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Cediranib	135.55
SIDM00218	THCA\|thyroid	p.D173Y (No)	GDSC	Foretinib	11.667
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Sunitinib	3.5803
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Sorafenib	14.1514
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Ponatinib	1.2453
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Cabozantinib	3.5647
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Linifanib	1.0581
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Foretinib	0.3025
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Tivozanib	1.8749
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Brivanib, BMS-540215	38.1602
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	BIBF-1120	14.3756
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Axitinib	4.2422
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Motesanib	40.399
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Sorafenib	8.8965
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Cediranib	5.7332
SIDM00580	LAML\|acute_myeloid_leukaemia	p.F1212C (No)	GDSC	Foretinib	1.5694
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Sunitinib	15.0793
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Ponatinib	1.0928
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Cabozantinib	53.0498
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Linifanib	16.1099
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Foretinib	4.2194
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Tivozanib	1.9725
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Brivanib, BMS-540215	79.1743
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	BIBF-1120	15.5854
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Axitinib	10.1635
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Motesanib	23.4403
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Sorafenib	14.032
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Cediranib	26.777
SIDM00306	UNCLASSIFIED\|lung_NSCLC_large_cell	p.T1339I (Yes)	GDSC	Foretinib	13.168
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Sunitinib	126.1618
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Sorafenib	7.3666
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Ponatinib	1.0396
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Cabozantinib	5.6926
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Linifanib	7.1256
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Foretinib	1.0657
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Tivozanib	1.5312
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Brivanib, BMS-540215	59.0675
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	BIBF-1120	108.8012
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Axitinib	5.6293
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Motesanib	27.0296
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Sorafenib	29.602
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Cediranib	9.6316
SIDM00490	GBM\|glioma	p.V1041L (No)	GDSC	Foretinib	1.6438
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Ponatinib	8.3321
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Cabozantinib	30.1187
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Linifanib	11.7738
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Foretinib	1.5715
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Tivozanib	2.1142
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Brivanib, BMS-540215	42.1606
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	BIBF-1120	10.8231
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Axitinib	9.3735
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Motesanib	32.8628
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Sorafenib	76.851
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Cediranib	2.4313
SIDM00611	KIRC\|kidney	p.S1037L (No)	GDSC	Foretinib	11.908
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Sunitinib	15.4202
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Sorafenib	57.7181
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Ponatinib	1.9397
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Cabozantinib	19.1626
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Linifanib	20.6562
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Foretinib	0.5741
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Tivozanib	2.1578
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Brivanib, BMS-540215	28.3853
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	BIBF-1120	25.5856
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Axitinib	4.0786
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Motesanib	40.0823
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Sorafenib	7.1912
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Cediranib	2.0788
SIDM01259	ALL\|lymphoblastic_leukemia	p.V1177L (No)	GDSC	Foretinib	1.8666
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Sunitinib	15.4202
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Sorafenib	57.7181
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Ponatinib	1.9397
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Cabozantinib	19.1626
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Linifanib	20.6562
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Foretinib	0.5741
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Tivozanib	2.1578
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Brivanib, BMS-540215	28.3853
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	BIBF-1120	25.5856
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Axitinib	4.0786
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Motesanib	40.0823
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Sorafenib	7.1912
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Cediranib	2.0788
SIDM01259	ALL\|lymphoblastic_leukemia	p.G174V (No)	GDSC	Foretinib	1.8666
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Ponatinib	1.9526
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Cabozantinib	8.3183
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Linifanib	0.9776
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Foretinib	1.1726
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Tivozanib	1.2326
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Brivanib, BMS-540215	108.0195
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	BIBF-1120	12.4791
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Axitinib	4.497
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Motesanib	9.6673
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Sorafenib	6.3081
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Cediranib	6.2083
SIDM00537	COREAD\|large_intestine	p.L415V (No)	GDSC	Foretinib	1.3073
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Sunitinib	11.0351
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Sorafenib	8.4394
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Ponatinib	0.6336
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Cabozantinib	9.9816
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Linifanib	0.289
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Foretinib	0.5928
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Tivozanib	0.9947
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Brivanib, BMS-540215	94.7947
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	BIBF-1120	49.7188
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Axitinib	20.0647
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Motesanib	27.4647
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Sorafenib	4.9857
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Cediranib	12.852
SIDM00374	DLBC\|B_cell_lymphoma	p.P64L (No)	GDSC	Foretinib	2.043
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Sunitinib	67.5213
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Sorafenib	73.9548
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Ponatinib	11.0034
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Cabozantinib	41.8362
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Linifanib	14.5522
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Foretinib	1.9663
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Tivozanib	1.7912
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Brivanib, BMS-540215	91.5106
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	BIBF-1120	28.9637
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Axitinib	37.3897
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Motesanib	15.5156
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Sorafenib	14.353
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Cediranib	50.947
SIDM00653	SCLC\|lung_small_cell_carcinoma	p.D392N (No)	GDSC	Foretinib	9.8277
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Sunitinib	27.0556
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Sorafenib	3.7949
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Ponatinib	4.2843
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Cabozantinib	31.0827
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Linifanib	16.66
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Foretinib	4.5059
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Tivozanib	2.1452
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Brivanib, BMS-540215	18.1438
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	BIBF-1120	6.7933
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Axitinib	12.8183
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Motesanib	33.3661
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Axitinib	10.074
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Sorafenib	3.3717
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Cediranib	36.443
SIDM00562	BRCA\|breast	p.G494E (No)	GDSC	Foretinib	3.0689
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Sorafenib	5.3544
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Ponatinib	0.1539
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Cabozantinib	7.319
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Linifanib	15.6177
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Foretinib	0.3701
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Tivozanib	1.0384
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Brivanib, BMS-540215	7.9866
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	BIBF-1120	5.1981
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Axitinib	6.6141
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Motesanib	30.7019
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Sorafenib	6.4979
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Cediranib	4.6927
SIDM00416	DLBC\|B_cell_lymphoma	p.K630T (No)	GDSC	Foretinib	0.704
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Ponatinib	0.6427
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Cabozantinib	24.5766
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Linifanib	11.3834
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Foretinib	0.9473
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Tivozanib	1.8289
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Brivanib, BMS-540215	52.9136
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	BIBF-1120	35.941
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Axitinib	27.0347
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Motesanib	2.6626
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Sorafenib	22.114
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Cediranib	11.978
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.R791Q (No)	GDSC	Foretinib	3.9586
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Ponatinib	0.6427
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Cabozantinib	24.5766
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Linifanib	11.3834
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Foretinib	0.9473
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Tivozanib	1.8289
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Brivanib, BMS-540215	52.9136
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	BIBF-1120	35.941
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Axitinib	27.0347
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Motesanib	2.6626
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Sorafenib	22.114
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Cediranib	11.978
SIDM01219	UNCLASSIFIED\|lung_NSCLC_large_cell	p.G255R (No)	GDSC	Foretinib	3.9586
SIDM00193	COREAD\|large_intestine	p.R1232Q (No)	GDSC	Cabozantinib	133.9123
SIDM00193	COREAD\|large_intestine	p.R1232Q (No)	GDSC	Linifanib	15.5526
SIDM00193	COREAD\|large_intestine	p.R1232Q (No)	GDSC	Foretinib	7.8838
SIDM00193	COREAD\|large_intestine	p.R1232Q (No)	GDSC	Tivozanib	1.8904
SIDM00193	COREAD\|large_intestine	p.R1232Q (No)	GDSC	Brivanib, BMS-540215	511.1612
SIDM00193	COREAD\|large_intestine	p.R1232Q (No)	GDSC	BIBF-1120	524.2554
SIDM00193	COREAD\|large_intestine	p.R1232Q (No)	GDSC	Axitinib	12.6981
SIDM00193	COREAD\|large_intestine	p.R1232Q (No)	GDSC	Motesanib	50.1977
SIDM00193	COREAD\|large_intestine	p.E705D (No)	GDSC	Cabozantinib	133.9123
SIDM00193	COREAD\|large_intestine	p.E705D (No)	GDSC	Linifanib	15.5526
SIDM00193	COREAD\|large_intestine	p.E705D (No)	GDSC	Foretinib	7.8838
SIDM00193	COREAD\|large_intestine	p.E705D (No)	GDSC	Tivozanib	1.8904
SIDM00193	COREAD\|large_intestine	p.E705D (No)	GDSC	Brivanib, BMS-540215	511.1612
SIDM00193	COREAD\|large_intestine	p.E705D (No)	GDSC	BIBF-1120	524.2554
SIDM00193	COREAD\|large_intestine	p.E705D (No)	GDSC	Axitinib	12.6981
SIDM00193	COREAD\|large_intestine	p.E705D (No)	GDSC	Motesanib	50.1977
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Sorafenib	2.2419
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Ponatinib	6.496
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Cabozantinib	28.7329
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Linifanib	12.9878
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Foretinib	3.6532
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Tivozanib	1.6445
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Brivanib, BMS-540215	110.6657
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	BIBF-1120	53.3315
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Axitinib	18.812
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Motesanib	6.3211
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Sorafenib	7.5049
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Cediranib	5.8015
SIDM00118	COREAD\|large_intestine	p.Q37H (No)	GDSC	Foretinib	4.088
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	Sunitinib	6.1015
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	Sorafenib	47.6718
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	Ponatinib	4.5028
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	Cabozantinib	6.1357
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	Linifanib	17.0511
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	Foretinib	0.4155
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	Tivozanib	3.0378
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	Brivanib, BMS-540215	284.6675
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	BIBF-1120	20.1618
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	Axitinib	10.2451
SIDM00086	KIRC\|kidney	p.L625S (No)	GDSC	Motesanib	19.4607

DegronMD: protein-targeted degradation, mutation and drug response to degrons

Degron: DSGTTLS

Degron related mutations and impact score

Drug responses associated with KDR mutations

All proteins holding degron of DSGTTLS

Uniprot ID	Source protein	Degron class	Location	Hit	E3 ligase	Degron score	Detail
P35968	Vascular endothelial growth factor receptor 2	DEG_SCF_TRCP1_1	1346:1352	DSGTTLS	BTRC	0.7404	More...